体脊柱的治疗性重塑可以防止损伤
Rebekah J Nicholson1, Luis Cedeño-Rosario2, J Alan Maschek3
1Department of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT, USA; Diabetes and Metabolism Research Center, University of Utah College of Medicine, Salt Lake City, UT, USA.
Cell metabolism
|November 13, 2025
概括
急性损伤 (AKI) 涉及管中有害脂质的积累. 向二胺脱酶1 (DES1) 保护线粒体并防止脏损伤,提供了一种新的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 线粒体生物学 线粒体生物学
- 脂质代谢 脂质代谢是什么
背景情况:
- 靠近管 (PT) 脂质代谢在急性损伤 (AKI) 病原发生过程中至关重要.
- AKI与PT中脂毒胺的增加有关,影响功能.
- 尿胺作为生物标志物用于儿童和成人群体的AKI严重程度.
研究的目的:
- 在AKI期间阐明胺在PT线粒体功能障碍中的作用.
- 为了确定陶胺破坏线粒体完整性的特定分子机制.
- 探索二基胺脱酶1 (DES1) 作为AKI的潜在治疗标.
主要方法:
- 在人类和小鼠AKI模型中分析PT胺.
- 热蛋白质分析,以确定初级PTs中的陶效应剂.
- 在遭受缺血-再输液损伤的小鼠中,DES1的遗传除.
- 评估线粒体结构,功能和呼吸能力.
主要成果:
- AKI在PT中诱导脂毒胺生物合成,与疾病严重程度相关.
- 胺破坏了线粒体接触点和状组织系统 (MICOS) 和呼吸系统超级复合体.
- 对于陶胺诱导的线粒体损伤,DES1活性至关重要.
- DES1淘汰赛小鼠表现出维护的线粒体完整性和对AKI的保护.
- 新的DES1抑制剂复制了DES1淘汰的保护作用.
结论:
- 由于DES1活性而产生的胺积累驱动了AKI中PT线粒体损伤.
- 针对DES1代表了AKI的一个有前途的治疗策略.
- 了解胺驱动的线粒体功能障碍为AKI治疗开辟了新的途径.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
254
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
254
01:29Acute Kidney Injury II: Pathophysiology
865
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
865
01:28Chronic Kidney Disease III: Interprofessional Care
331
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
331
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:20Acute Kidney Injury V: Interprofessional Care
287
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
287
01:11Renal Failure: Dose Adjustments
416
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
416